RESUMO
AIM: To reveal the effects of release-active antibodies to S100 protein in an animal model of multiple sclerosis. MATERIAL AND METHODS: Sixty female Wistar rats, aged 12 weeks, were included in the study. The pathology was induced by subcutaneous injection of the spinal cord homogenate. Afterwards the rats received a water solution of release-active antibodies to S100 protein (2,5 ml/kg/day, tenoten) or distilled water intragastrically during 30 days. Intramuscular injections of glatiramer acetate (4 mg/kg/day, copaxone) were used as a positive control. RESULTS AND CONCLUSION: Release-active antibodies to S100 protein enhanced the latency period of the disease, reduced its peak intensity and compensated the loss of body weight of the animals. The experimental drug effect was similar to the results of copaxone injections.
Assuntos
Anticorpos/uso terapêutico , Encefalomielite Autoimune Experimental/tratamento farmacológico , Esclerose Múltipla/tratamento farmacológico , Proteínas S100/imunologia , Animais , Anticorpos/administração & dosagem , Encefalomielite Autoimune Experimental/imunologia , Feminino , Acetato de Glatiramer , Esclerose Múltipla/imunologia , Peptídeos/administração & dosagem , Peptídeos/uso terapêutico , Ratos WistarRESUMO
The use of afala in patients with benign prostatic hyperplasia and moderate urination disturbances reduced the symptoms of the disease, improved urodynamic parameters, and increased quality of life. Clinical efficiency of afala was comparable with the efficiency of Serenoa repens extract (reference preparation).
Assuntos
Anticorpos/uso terapêutico , Fatores Imunológicos/uso terapêutico , Hiperplasia Prostática/tratamento farmacológico , Adulto , Idoso , Anticorpos/efeitos adversos , Anticorpos/farmacologia , Humanos , Fatores Imunológicos/farmacologia , Masculino , Pessoa de Meia-Idade , Hiperplasia Prostática/patologia , Qualidade de Vida , Resultado do Tratamento , Urodinâmica/efeitos dos fármacosRESUMO
We studied the effects of antibodies against interferon-gamma, erythropoietin, and tumor necrosis factor-alpha in ultralow doses on the production of endogenous interferon-gamma. Course peroral treatment with potentiated antibodies to interferon-gamma in various dilutions produced similar changes in experimental animals. The treatment stimulated spontaneous production of endogenous interferon-gamma by mouse lymphocytes. It should be emphasized that antibodies to other cytokines in ultralow doses did not stimulate interferon-gamma production. These data illustrate the specificity of action of antibodies to endogenous regulators in ultralow doses.
Assuntos
Anticorpos/farmacologia , Interferon gama/biossíntese , Interferon gama/imunologia , Administração Oral , Animais , Anticorpos/administração & dosagem , Relação Dose-Resposta a Droga , Eritropoetina/imunologia , Linfócitos/efeitos dos fármacos , Masculino , Camundongos , Fator de Necrose Tumoral alfa/imunologiaRESUMO
Single and repeated administration of ultralow doses of antibodies to erythropoietin did not increase the count of aberrant metaphases in bone marrow cells of BALB/c mice and were not genotoxic for Drosophila melanogaster wing cells in the test of somatic mosaicism.